Episode 160 - October 24, 2025

0:00-58:42

On this week’s episode, Chris Garabedian, Brian Skorney, and Sam Fazeli open with optimism about the biotech market, predicting an upcoming acceleration in IPO activity. In deals and financing news, the co-hosts discussed Summit Therapeutics’ $500 million raise, with more than half coming from insiders, and continued momentum in M&A, including Alkermes’ $2.1 billion acquisition of Avadel for its narcolepsy drug. The group also highlighted Takeda’s $1.2 billion oncology deal with Innovent. European biotech funding showed positive signs, evidenced by Tubulis’ $360 million Series C. Next, the co-hosts recapped ESMO, spotlighting Summit and Akeso’s NSCLC data, Incyte’s KRAS G12D inhibitor, and Arcus and AstraZeneca’s TIGIT data. The episode concluded with additional data readouts, including mixed results from Alector and GSK’s dementia drug, and Moderna’s CMV mRNA vaccine results. *This episode aired on October 24, 2025.

Publisher

Biotech Hangout

Link

podcasters.spotify.com/pod/show/biotechhangout/episodes/Episode-160---October-24--2025-e3a0n2f

Published

October 24, 2025

Duration

59 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

BH

Biotech Hangout

@biotechhangout

#october #lifesciences

The Nile